Security
Bioadaptives, Inc. Common Stock · BDPT
BDPTOTCCommon stockCurrentCIK 1575142Updated Oct 7, 2026
Name history
APEX 8 Inc. · through Aug 19, 2013
BDPT price & chart
Loading TradingView…
OTC:BDPT on TradingView ↗About the company
BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the health and wellness industry. We are dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Our mission is to improve the quality of life for our customers by offering products that support optimal health and vitality.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 124,360Source | 46,393Source | 78,767Source | 272,515Source | 8,735Source | 135,949Source | 110,448Source | 58,667Source | 225,901Source | 261,885Source | 103,998Source | 37,314Source |
| Property, Plant and EquipmentUSD | 15,500Source | — | 11,000Source | 17,000Source | — | 12,500Source | — | — | — | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | 18,000Source | 14,000Source | — | 15,166Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | — | — | — | — | 215,205Source | 261,885Source | 60,776Source | 25,405Source |
| Inventory, NetUSD | 44,228Source | 0Source | 36,046Source | 39,574Source | 6,000Source | 42,968Source | 40,584Source | 18,572Source | 44,706Source | 19,115Source | 15,281Source | 8,877Source |
| Assets, CurrentUSD | 108,860Source | 46,393Source | 67,767Source | 255,515Source | 8,735Source | 123,449Source | 110,448Source | 40,667Source | 211,901Source | 261,885Source | 88,557Source | 34,324Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,589,570Source | 1,851,754Source | 1,844,874Source | 1,407,813Source | 1,930,447Source | 2,272,091Source | 1,681,502Source | 1,856,550Source | 2,355,957Source | 1,725,803Source | 1,750,629Source | 1,488,815Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,093Source | 123,173Source | 3,659Source | 994Source | 123,173Source | 1,200Source | 904Source | 115,477Source | 1,200Source | 821Source | 89,576Source | 25,255Source |
| Additional Paid in CapitalUSD | 8,437,322Source | 6,861,859Source | 8,918,181Source | 8,387,834Source | 6,708,259Source | 8,700,704Source | 7,794,260Source | 6,656,867Source | 8,595,711Source | 7,704,343Source | 6,527,428Source | 6,074,763Source |
| Retained Earnings (Accumulated Deficit)USD | -9,897,858Source | -8,791,518Source | -10,682,200Source | -9,518,356Source | -8,753,869Source | -10,832,290Source | -9,360,442Source | -8,570,852Source | -10,721,204Source | -9,163,306Source | -8,264,145Source | -7,551,679Source |
| Stockholders' Equity Attributable to ParentUSD | -1,465,210Source | -1,805,361Source | -1,766,107Source | -1,135,298Source | -1,921,712Source | -2,136,142Source | -1,571,054Source | -1,797,883Source | -2,130,056Source | -1,463,918Source | -1,646,631Source | -1,451,501Source |
| Liabilities and EquityUSD | 124,360Source | 46,393Source | 78,767Source | 272,515Source | 8,735Source | 135,949Source | 110,448Source | 58,667Source | 225,901Source | 261,885Source | 103,998Source | 37,314Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,589,570Source | 1,851,754Source | 1,844,874Source | 1,407,813Source | 1,930,447Source | 2,272,091Source | 1,681,502Source | 1,856,550Source | 2,355,957Source | 1,725,803Source | 1,750,629Source | 1,488,815Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 6,939Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 162,177Source | 238,609Source | — | 152,847Source | 231,534Source | 180,837Source | 145,953Source | 215,973Source | — | 137,955Source | 1,015Source |
| Accounts Receivable | —Source | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -111,086Source | -197,136Source | -1,557,898Source | -899,161Source | -712,466Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | 28,670Source | — | — | 28,670Source | — | — | 0Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | 59Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -1,738Source | 21,469Source | 25,591Source | — | 6,404Source | 4,127Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -84,839Source | -97,906Source | -516,025Source | -249,517Source | -223,773Source | -227,259Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -18,000Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 18,000Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 555,000Source | 326,211Source | 259,144Source | 169,728Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | — | -57,531Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 59,273Source | 43,893Source | 29,221Source | 210,582Source | 73,606Source | 39,564Source | 158,445Source | 137,470Source | 60,776Source | 25,405Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 4,728Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 0Source | 75,000Source | 0Source | 19,941Source | 28,174Source | 62,148Source |
| DepreciationUSD | — | — | — | — | 1,500Source | 1,000Source | 1,500Source | 0Source | 4,000Source | — | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | -201,360Source | 93,989Source | 446,730Source | 130,954Source | 174,884Source | 61,659Source | -578,645Source | -210,043Source | -307,412Source | -184,401Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | -61,659Source | 578,645Source | 210,043Source | 307,412Source | 184,401Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 101,700Source | — | 15,574Source | 0Source | — | — | 133,800Source | — | -13,200Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 250,971Source | 40,396Source | 177,745Source | 197,892Source | 181,050Source | 143,383Source | 820,508Source | 335,306Source | 101,478Source | 254,119Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -37,649Source | — | — | — | -197,136Source | — | -904,761Source | -712,466Source | -895,570Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | 0Source |
| Inventory Write-downUSD | — | — | 0Source | 60,000Source | 0Source | 0Source | — | — | 0Source | — | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | 0Source | — | — | — | — | — | 0Source | -42Source | -148Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -379,502Source | -37,649Source | 150,090Source | -157,914Source | -111,086Source | -197,136Source | -1,557,898Source | -899,161Source | -712,466Source | -895,570Source |
| Operating ExpensesUSD | — | — | 269,540Source | 121,941Source | 201,416Source | 280,282Source | 202,331Source | 249,148Source | 1,054,670Source | 606,120Source | 239,740Source | 429,026Source |
| Other Nonoperating Income (Expense)USD | — | — | -113,813Source | 84,292Source | 347,266Source | 121,305Source | 87,132Source | 52,012Source | -515,725Source | -297,071Source | -483,545Source | -473,670Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 0Source | 178,100Source | 271,587Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | — | — | 28,670Source | — | — | — |
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | — | — | — | — | — |
| InterestExpenseNonoperating | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 4,632Source | 0Source | 4,988Source | 3,219Source | 5,514Source | 0Source | 18,278Source | 12,669Source | 28,565Source | 17,176Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -265,689Source | -121,941Source | -197,176Source | -279,219Source | -198,218Source | -249,148Source | -1,042,173Source | -602,090Source | -228,921Source | — |
| Other Nonoperating Income (Expense)USD | — | — | -113,813Source | 84,292Source | 347,266Source | 121,305Source | 87,132Source | 52,012Source | -515,725Source | -297,071Source | -483,545Source | -473,670Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -379,502Source | -37,649Source | 150,090Source | -157,914Source | -111,086Source | -197,136Source | -1,557,898Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -379,502Source | -37,649Source | 150,090Source | -157,914Source | -111,086Source | -197,136Source | -1,557,898Source | -899,161Source | -712,466Source | -895,570Source |
| Earnings Per Share, BasicUSD per share | — | — | — | 0Source | 0.01Source | -0.02Source | — | — | — | -0.11Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.04Source | 0Source | 0Source | -0.02Source | -0.01Source | -0.02Source | -0.15Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 895,760,225Source | 14,192,536Source | 9,533,375Source | — | — | — | 8,215,426Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 10,239,290Source | 8,211,526Source | 281,196,262Source | 9,533,375Source | 12,008,725Source | 9,048,725Source | 10,072,563Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 0Source | 75,000Source | 0Source | 19,941Source | 28,174Source | 62,148Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | -61,659Source | 578,645Source | 210,043Source | 307,412Source | 184,401Source |
| General and Administrative ExpenseUSD | — | — | 250,971Source | 40,396Source | 177,745Source | 197,892Source | 181,050Source | 143,383Source | 820,508Source | 335,306Source | 101,478Source | 254,119Source |
| Gross ProfitUSD | — | — | 3,851Source | 0Source | 4,240Source | 1,063Source | 4,113Source | 0Source | 12,497Source | 4,030Source | 10,819Source | 7,126Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -37,649Source | — | — | — | -197,136Source | — | -904,761Source | -712,466Source | -895,570Source |
| Interest ExpenseUSD | — | — | 14,153Source | 9,697Source | — | 9,649Source | 87,757Source | 9,647Source | 70,880Source | 91,978Source | 162,891Source | 289,121Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | 15,561Source | 9,330Source | 44,466Source | 38,278Source | 43,062Source | 49,402Source |
| Operating ExpensesUSD | — | — | 269,540Source | 121,941Source | 201,416Source | 280,282Source | 202,331Source | 249,148Source | 1,054,670Source | 606,120Source | 239,740Source | 429,026Source |
| Other IncomeUSD | — | — | 0Source | — | — | 0Source | 5Source | 0Source | 0Source | 4,950Source | — | — |
| Interest Expense (non-operating) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | — | — | — | — | — |
Filing attachments
bdpt_ex991.htm · 8-K · 2025-03-18
EX-99.1 2 bdpt_ex991.htm PRESS RELEASE bdpt_ex991.htm EXHIBIT 99.1 Zeranovia™ Weight Loss Product Shows Promising Results in Dosage Trial LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone. During the trial, partici…
Read attachment ↗